^
    3d
    A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=20, Suspended, Shanghai 6th People's Hospital | Recruiting --> Suspended | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial suspension • Trial primary completion date
    |
    Fruzaqla (fruquintinib) • Enweida (envafolimab)
    4d
    Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, RenJi Hospital | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Fruzaqla (fruquintinib) • Hetronifly (serplulimab)
    6d
    FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma. (PubMed, Dig Liver Dis)
    ENGIC 06 - PRODIGE 114 - FFCD 2401 - FRUQUITAS is designed to determine whether VEGFR inhibition with fruquintinib plus trifluridine/tipiracil can meaningfully improve survival outcomes in pre-treated mOGC.
    P3 data • Journal
    |
    FLT1 (Fms-related tyrosine kinase 1)
    |
    Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    7d
    FRUQUITAS: Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma (clinicaltrials.gov)
    P3, N=324, Recruiting, Federation Francophone de Cancerologie Digestive
    Trial initiation date
    |
    CLDN18 (Claudin 18)
    |
    Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    16d
    Prior response to anti-VEGF agents predicts the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer. (PubMed, Int J Clin Oncol)
    The response to anti-VEGF agents in second-line therapy may predict the efficacy of FTD/TPI + Bev in subsequent treatments.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • RAS mutation
    |
    Avastin (bevacizumab) • Stivarga (regorafenib) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    20d
    FREEDOM: Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=150, Not yet recruiting, Harbin Medical University
    New trial
    |
    paclitaxel • docetaxel • albumin-bound paclitaxel • irinotecan • Fruzaqla (fruquintinib)
    24d
    Exploratory Study of Bifidobacterium Combined with Fruquintinib and Immune Checkpoint Inhibitors in the Treatment of Refractory MSS-type Advanced Colorectal Cancer (ChiCTR2600120801)
    P=N/A, N=30, Quzhou People's Hospital; Quzhou People's Hospital
    New trial • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Fruzaqla (fruquintinib)
    24d
    Envafolimab, Fruquintinib plus SBRT (ENCO) as Third-Line+ Therapy for MSS Metastatic Colorectal Cancer: An Exploratory Single-Arm, Single-Center Study (ChiCTR2600120595)
    P=N/A, N=30, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School; Nanjing Drum Tower Hospital, The Affiliated Hospital of Nan
    New trial
    |
    Fruzaqla (fruquintinib) • Enweida (envafolimab)
    24d
    Observational study on the combination of fruquintinib and standard chemotherapy in the treatment of advanced gastric cancer (ChiCTR2600119681)
    P=N/A, N=50, Completed, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New trial
    |
    HER-2 positive
    |
    Fruzaqla (fruquintinib)
    25d
    Exploratory Clinical Study of Fruquintinib Combined with Sintilimab and Chemotherapy as Adjuvant Treatment for Stage III Gastric Cancer after Surgery (ChiCTR2500114651)
    P4, N=30, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
    25d
    Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study. (PubMed, Commun Med (Lond))
    Fruquintinib plus sintilimab may indicate favourable and durable antitumour activity with a manageable safety profile in advanced cervical cancer, especially in pretreated patients with PD-L1 CPS ≥1, warranting further investigation.
    P2 data • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
    1m
    SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study (clinicaltrials.gov)
    P2, N=12, Not yet recruiting, Meng Qiu
    New P2 trial
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Fruzaqla (fruquintinib)